Fetzima, also known as levomilnacipran extended-release capsules, was first approved by the U.S. Food and Drug Administration (FDA) on July 31, 2013 [1].
When did Fetzima become available in pharmacies?
Following its FDA approval in July 2013, Fetzima became commercially available to patients shortly thereafter [1].
What is Fetzima used to treat?
Fetzima is indicated for the treatment of major depressive disorder (MDD) in adults [1].
What is the difference between Fetzima and other antidepressants?
Fetzima is a serotonin-norepinephrine reuptake inhibitor (SNRI) [1]. It works by increasing the levels of certain natural substances in the brain, specifically serotonin and norepinephrine, which are thought to help improve mood [1]. This mechanism of action distinguishes it from other classes of antidepressants, such as selective serotonin reuptake inhibitors (SSRIs) or tricyclic antidepressants.
What are the potential side effects of Fetzima?
Common side effects reported with Fetzima include nausea, constipation, insomnia, increased sweating, and heart rate increase [1]. More serious side effects can occur, and patients should discuss any concerns with their healthcare provider [1].
What is the patent status for Fetzima?
Information regarding the specific patent expiration dates for Fetzima is available through resources like DrugPatentWatch.com, which tracks pharmaceutical patents [2]. The patent landscape for a drug can be complex and may involve multiple patents covering different aspects of the drug and its use [2].
When might generic versions of Fetzima be available?
The availability of generic versions of Fetzima is dependent on patent expiration and any regulatory approvals for generic manufacturers [2]. DrugPatentWatch.com can provide detailed information on patent filings and their projected expiry [2].
---
Sources:
[1] U.S. Food & Drug Administration. (2013, July 31). FDA approves Fetzima (levomilnacipran extended-release capsules). https://www.fda.gov/drugs/postmarket-drug-safety-information-pharmacists/fetzima-levomilnacipran-extended-release-capsules-information
[2] DrugPatentWatch.com. (n.d.). Fetzima. Retrieved from https://drugpatentwatch.com/